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Leukocytoclastic vasculitis (LV) is characterized by neu-
trophilic invasion and fibrinoid necrosis along with endo-
thelial enlargement in postcapillary venules. Annular ap-
pearance of LV (ALV) is rare, but it can be accompanied by 
several systemic diseases. One of these systemic diseases is 
ulcerative colitis (UC), a subgroup of inflammatory bowel 
disease. Only one case was previously reported in which 
ALV was associated with UC, and herein we present one 
more case. A 66-year-old woman presented with painful 
polycyclic erythema on both palms, which had been present 
for 4 days. She had suffered from UC for 5 years. The patient 
had no fever or other systemic symptoms, and histological 
examination demonstrated typical LV. 200 mg of oral dap-
sone was taken daily to rapidly reduce her symptoms and 
signs, and after 1 week all lesions resolved completely with-
out any adverse events. ALV is not a distinct condition and it 
can appear in a broad range of small vessel vasculitides. 
Although ALV in patients with UC is a very rare combination, 
clinicians need to be aware of this possible association. (Ann 
Dermatol 23(S3) S338∼S340, 2011)
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INTRODUCTION
Ulcerative colitis (UC) is a subgroup of inflammatory 
bowel disease (IBD). It is diffusive inflammation limited to 
the large intestinal mucosa. There can be many extra- 
gastrointestinal symptoms with the progress of IBD. Skin 
manifestations such as pyoderma gangrenosum and ery-
thema nodosum usually occur in conjunction with 
Crohn’s disease and UC. However, other skin diseases, 
such as leukocytoclastic vasculitis (LV) has rarely been 
reported. Skin manifestations are important clues for dia-
gnosis because they may precede gastrointestinal symp-
toms
1. 
LV is characterized by neutrophilic invasion and fibrinoid 
necrosis along with endothelial enlargement in post-
capillary venules. It is a syndrome in which patients most 
commonly present with palpable purpura on lower 
extremities and ankles
2. An annular variant of LV is rare 
and to date, only 15 cases have been reported
3.
Association between annular leukocytoclastic vasculitis 
(ALV) and UC is very uncommon and to the best of our 
knowledge, this is only the second report. We report a 
case diagnosed as ALV 5 years after the development of 
UC, which is highly rare. 
CASE REPORT
A 66-year-old woman presented with painful polycyclic 
erythema on both palms. She had been diagnosed with 
UC 5 years earlier. Her UC had been well controlled with 
mesalazine and aspirin since June 2006. She was hos-
pitalized in April 2009 due to gastrointestinal tract bloody 
excrement caused by worsening of the UC. The dose of 
mesalazine was increased and a fair response to the 
symptoms of the UC was observed. In June 2009, 4 days 
before visiting our department, confluent annular ery-Annular LCV in Patient with UC
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Fig. 1. Multiple confluent annular purpuric erythema with central
clearing on both palms.
Fig. 2. Leukocytoclastic vasculitis. 
There was a heavy infiltrate of neu-
trophils with leukocytoclasis and fi-
brinoid necrosis of vessel wall (H&
E, original magnification ×400).
thema appeared on both palms. The pain was not severe, 
but tenderness was accompanied and the lesions became 
larger. Therefore, she was referred to our department. Her 
family history was unremarkable and there was no pre-
vious history of any skin disease or skin allergy. 
The laboratory test showed elevated erythrocyte sedimen-
tation rate: 66 mm/hr (normal: 0∼20) and elevated C-re-
active protein: 3.48 mg/dl (normal: 0∼0.05). The com-
plete blood count and routine chemistry were within 
normal range.
Multiple confluent annular erythematous patches were 
observed on both palms (Fig. 1). A skin biopsy performed 
on an erythematous part of the palm demonstrated the 
presence of lymphohistocytic infiltration around the blood 
vessels of the upper dermis, edema of endothelial cells 
and extravasation of erythrocytes (Fig. 2). Diagnosis of   
ALV was confirmed. The patient was treated with dapsone 
200 mg/day, aceclofenac 200 mg/day, levocetirizine 5 
mg/day and fexofenadine 180 mg/day for 1 week fol-
lowing biopsy. Her symptoms and signs were completely 
gone without sequelae.
 
DISCUSSION
 
Extra-intestinal manifestations of IBDs including muco-
cutaneous involvement and skin manifestations occur in 
about 15% of patients with inflammatory bowel disor-
ders
4. The most common skin manifestations are pyo-
derma gangrenosum and erythema nodosum, while necro-
tizing vasculitis, cutaneous polyarteritis nodosa and gra-
nulomatous perivasculitis are less frequently observed
5. In 
the present case, intestinal manifestations of UC were 
associated with uncommon skin lesions characterized by 
confluent annular erythema, which was diagnosed as 
ALV. Since the skin lesions developed 1∼2 months after 
the UC worsened, we speculated that there may be an 
association between the two conditions
ALV is not a clear status within LV, classified based on the 
clinical morphology. Cribier et al. first reported that some 
patients with ALV constitute a distinct subtype, which 
satisfies the following criteria
6. The characteristics are: (1) 
multiple attacks over years with sudden onset and spon-
taneous regression after 7∼10 days, (2) annular purpuric 
patches that show centrifugal extension, (3) extension over 
the limbs and trunk creating polycyclic lesions that clear 
leaving mild haemosiderin deposition, (4) no extracu-
taneous symptoms and good general health, (5) histol-
ogical changes of LV with mild vascular changes and 
intense polymorphonuclear cell infiltration, and (6) com-
plete clearance of all lesions with dapsone
6. Our case 
matches the second, fifth and sixth criteria established by 
Cribier. Therefore, we cannot classify this case as a “dis-JS Hong, et al
S340 Ann Dermatol
tinct subtype”; however, we thought that there was 
enough evidence to categorize this case morphologically 
as ALV. Also, the most potent treatment for ALV is dap-
sone.
There have been about 20 cases in the literature des-
cribing ALV in association with systemic diseases such as 
monoclonal gammopathy, sarcoidosis, UC, myelomatosis, 
pregnancy and chronic hepatitis B
3,7-10. Association bet-
ween ALV and UC is very uncommon and , to the best of 
our knowledge, this is only the second report.
The etiology of LV with UC is not clear; a partial defect of 
immunity common to the skin and intestines has been 
suggested
11. The causes of immune activation are believed 
to be due to the presence of antigens related to infectious 
agents, drugs, neoplasia, food, or autoantigens
12. Attrac-
ted neutrophils due to immune activation release lysoso-
mal enzymes, which induce nitric oxide (NO). NO causes 
apoptosis of neutrophils leading to leukocytoclasis
13. At 
present, the clinical characteristics of ALV, annularity and 
peripheral spreading, are not known. However, it is 
possible that inflammatory cells, inflammatory mediators 
and antigens spread peripherally resulting in an annular 
pattern of erythema
14.
One possible hypothesis for the association between ALV 
and UC is that the pathogenesis of both is based on 
immune mechanisms and deposition of immune com-
plexes in the vascular structure and intestinal mucosa for 
ALV and UC, respectively
15.
Skin lesions of LV can be treated with corticosteroids, 
dapsone, colchicine, or immunosuppressive agents
2. In 
contrast, in ALV, the most potent and effective treatment is 
dapsone at a daily dosage of 100 mg to 200 mg. 
Although ALV in patients with UC is a very rare com-
bination, clinicians need to be aware of this possible 
association and the most effective treatment for ALV is 
dapsone.
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